Hi

MindBio is pleased to report it has completed its 6-month milestone post treatment with MB22001 in a Phase 2A microdosing depression trial and will be releasing the data in the coming fortnight.

Photo: Justin Hanka, MindBio CEO and Co-Founder inspecting 1 million GMP grade microdoses of LSD!

To date, MindBio has reported long term shelf stability data for its lead candidate drug MB22001 at 12 months. We have reported improvements in mood from clinical trials, including statistically significant and clinically meaningful improvements in trial participant's subjective feelings of "happiness", "creativity", "energy", "wellness" and feelings of "social connectivity" as well as reduced feelings of "anger" and "irritability".

Surprisingly, we also noted statistically significant improvements in sleep, the day after microdosing! We noted improvements in REM, time of sleep and quality of sleep.

We were not surprised to see a 60% improvement in depressive symptoms in our Phase 2A depression trial and a 53% complete remission from depression.

The data is compelling, that MB22001 and our microdosing treatment thesis is a safe, effective and scalable way to use psychedelic medicines to treat Major Depressive Disorder

We continue dosing in our two Phase 2B randomized controlled trials in Depression and another trial treating Existential Distress in late stage Cancer patients. We expect top line readouts circa in mid 2025.

We invite you to join us in support of creating a brighter future for mental health.

Stay Well!

JUSTIN HANKA

Chief Executive Officer & Co-Founder

MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)

Follow CEO Justin Hanka on LinkedIn:

https://www.linkedin.com/in/justinhanka/

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true